Progress in immune-drugs of Hemato-oncology

Abstract

Hematological tumors are a significant disease that poses a serious threat to human health, with morbidity and mortality rates ranking among the highest for all types of tumors. Targeted and immunotherapy for hematological tumors have made significant progress in various aspects, and the utilization of new drugs has enhanced the overall effectiveness of treating hematological tumors. As medicine enters a new era of personalized treatment, monoclonal antibody drugs, with their unique mechanism of action and high efficiency, play an immeasurably important role in the treatment of malignant tumors. Monoclonal antibodies are also utilized as targeting agents for delivering nanomedicines containing cytotoxic payloads or directly linked to cytotoxic drugs. The use of monoclonal antibodies has become a popular treatment for hematologic tumors, as evidenced by significant commercial success. The main features of monoclonal antibody drugs compared to traditional chemical drugs are that monoclonal antibodies are biological drugs with higher biotransformation efficiency, i.e., a higher success rate, and fewer side effects. However, targeted drug monotherapy often yields poor remission rates, and the efficacy and safety of immunotherapy need further enhancement. This article will begin by discussing hematological oncology and provide an overview of the principles, advantages, and disadvantages of several common monoclonal antibody drugs currently available on the market. It will also explore the potential for combined use of monoclonal antibodies, offering direction and assistance for future research in this field.